Characterisation of anti‐alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody MEDI4893 against Staphylococcus aureus alpha toxin

摘要

ObjectivesMEDI4893 is a novel, long‐acting human monoclonal antibody targeting Staphylococcus aureus (SA) alpha toxin (AT). This report presents the results of the exploratory analyses from a randomised phase 1 dose‐escalation study in healthy human subjects receiving single intravenous MEDI4893 doses or placebo.